{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:14:52Z","timestamp":1769584492941,"version":"3.49.0"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["LP110200126"],"award-info":[{"award-number":["LP110200126"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186137","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T18:00:43Z","timestamp":1508781643000},"page":"e0186137","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models"],"prefix":"10.1371","volume":"12","author":[{"given":"Mohamed A.","family":"Alfaleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-8686","authenticated-orcid":true,"given":"Christopher B.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Sedliarou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Gudhka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Vanegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia H.","family":"Suurbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"de Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bree A.","family":"Rumballe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"MacDiarmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"373S","DOI":"10.1378\/chest.103.4_Supplement.373S","article-title":"Natural history and epidemiology of malignant mesothelioma","volume":"103","author":"KH Antman","year":"1993","journal-title":"Chest"},{"issue":"9625","key":"ref2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"MF Muers","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"ref3","first-page":"283","article-title":"Asbestos bodies and mesothelioma","volume":"11","author":"J Stumphius","year":"1968","journal-title":"The Annals of occupational hygiene"},{"issue":"Suppl 5","key":"ref4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1289\/ehp.94102s519","article-title":"Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence","volume":"102","author":"JC Barrett","year":"1994","journal-title":"Environmental health perspectives"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.semdp.2006.08.002","article-title":"The pathogenesis of mesothelioma","volume":"23","author":"M Carbone","year":"2006","journal-title":"Seminars in diagnostic pathology"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"BT Mossman","year":"2013","journal-title":"The American journal of pathology"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","article-title":"Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways","volume":"42","author":"NH Heintz","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1539\/joh.16-2002-ST","article-title":"The global health dimensions of asbestos and asbestos-related diseases","volume":"58","author":"C Ramazzini","year":"2016","journal-title":"J Occup Health"},{"issue":"6","key":"ref9","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"N van Zandwijk","year":"2013","journal-title":"Journal of thoracic disease"},{"issue":"3\u20134","key":"ref10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"J Peto","year":"1999","journal-title":"British journal of cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"572609","DOI":"10.1155\/2013\/572609","article-title":"A potential therapeutic strategy for malignant mesothelioma with gene medicine","volume":"2013","author":"Y Tada","year":"2013","journal-title":"BioMed research international"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0360-3016(98)00409-X","article-title":"Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura\u2014a single-institution experience with 189 patients","volume":"43","author":"L de Graaf-Strukowska","year":"1999","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (Alimta)","volume":"9","author":"M Hazarika","year":"2004","journal-title":"The oncologist"},{"issue":"28","key":"ref14","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"JP van Meerbeeck","year":"2005","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2011.04.014","article-title":"Chemotherapy and targeted therapies for unresectable malignant mesothelioma","volume":"73","author":"RJ Kelly","year":"2011","journal-title":"Lung cancer"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0092-8674(89)90586-2","article-title":"A division inhibitor and a topological specificity factor coded for by the minicell locus determine proper placement of the division septum in E. coli","volume":"56","author":"PA de Boer","year":"1989","journal-title":"Cell"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2958.2004.04265.x","article-title":"Positioning of the MinE binding site on the MinD surface suggests a plausible mechanism for activation of the Escherichia coli MinD ATPase during division site selection","volume":"54","author":"L Ma","year":"2004","journal-title":"Molecular microbiology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev.biochem.75.103004.142652","article-title":"Assembly dynamics of the bacterial MinCDE system and spatial regulation of the Z ring","volume":"76","author":"J Lutkenhaus","year":"2007","journal-title":"Annual review of biochemistry"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccr.2007.03.012","article-title":"Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics","volume":"11","author":"JA MacDiarmid","year":"2007","journal-title":"Cancer cell"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/19420862.2014.985952","article-title":"Nanocell targeting using engineered bispecific antibodies","volume":"7","author":"K Taylor","year":"2015","journal-title":"mAbs"},{"issue":"17","key":"ref22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4161\/cc.6.17.4648","article-title":"Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors","volume":"6","author":"JA MacDiarmid","year":"2007","journal-title":"Cell Cycle"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"e0151832","DOI":"10.1371\/journal.pone.0151832","article-title":"Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model","volume":"11","author":"JA MacDiarmid","year":"2016","journal-title":"PloS one"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.jocn.2015.06.005","article-title":"First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma","volume":"22","author":"JR Whittle","year":"2015","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"e0144559","DOI":"10.1371\/journal.pone.0144559","article-title":"A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells","volume":"10","author":"BJ Solomon","year":"2015","journal-title":"PloS one"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nbt0709-620","article-title":"Minicells overcome tumor drug-resistance","volume":"27","author":"ED Karagiannis","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nbt.1547","article-title":"Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug","volume":"27","author":"JA MacDiarmid","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Z Tang","year":"2013","journal-title":"Anti-cancer agents in medicinal chemistry"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"A Destro","year":"2006","journal-title":"Lung cancer"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"A Rump","year":"2004","journal-title":"The Journal of biological chemistry"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"M Li","year":"2008","journal-title":"Molecular cancer therapeutics"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Molecular cancer research","volume":"6","author":"U Bharadwaj","year":"2008","journal-title":"MCR"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"U Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt\/PI3K\/NF-kappaB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"U Bharadwaj","year":"2011","journal-title":"Molecular cancer"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway","volume":"424","author":"MC Chang","year":"2009","journal-title":"The Biochemical journal"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"WF Cheng","year":"2009","journal-title":"British journal of cancer"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","article-title":"Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells","volume":"6","author":"N Uehara","year":"2008","journal-title":"Molecular cancer research: MCR"},{"key":"ref38","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"R Hassan","year":"2007","journal-title":"Cancer immunity"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"PS Chowdhury","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"M Ho","year":"2011","journal-title":"Int J Cancer"},{"issue":"23","key":"ref41","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1158\/1078-0432.CCR-07-1592","article-title":"Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts","volume":"13","author":"R Hassan","year":"2007","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"1\u20132","key":"ref42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-1759(99)00142-8","article-title":"Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations","volume":"231","author":"PS Chowdhury","year":"1999","journal-title":"J Immunol Methods"},{"issue":"23","key":"ref43","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"R Hassan","year":"2014","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncy.20071","article-title":"The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions","volume":"118","author":"F Hasteh","year":"2010","journal-title":"Cancer cytopathology"},{"issue":"4","key":"ref45","first-page":"411","article-title":"Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma","volume":"3","author":"K Pillai","year":"2013","journal-title":"American journal of cancer research"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3892\/etm.2012.511","article-title":"Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients","volume":"3","author":"M Kobayashi","year":"2012","journal-title":"Experimental and therapeutic medicine"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","article-title":"Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue\u2014a review","volume":"9","author":"N Fedchenko","year":"2014","journal-title":"Diagnostic pathology"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","article-title":"Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis","volume":"84","author":"G Koopman","year":"1994","journal-title":"Blood"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study","volume":"112","author":"B Ghanim","year":"2015","journal-title":"British journal of cancer"},{"issue":"4","key":"ref50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/COC.0b013e3182a0e867","article-title":"Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma","volume":"38","author":"K Pillai","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"G Reid","year":"2013","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models","volume":"13","author":"SJ Scales","year":"2014","journal-title":"Molecular cancer therapeutics"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/antib2020193","article-title":"In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments","volume":"2","author":"P Monnier","year":"2013","journal-title":"Antibodies"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.copbio.2009.07.002","article-title":"Next generation immunotherapeutics\u2014honing the magic bullet","volume":"20","author":"C Enever","year":"2009","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","article-title":"Molecular engineering and design of therapeutic antibodies","volume":"20","author":"LG Presta","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"27","key":"ref56","doi-asserted-by":"crossref","first-page":"23480","DOI":"10.18632\/oncotarget.4346","article-title":"miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma","volume":"6","author":"M Williams","year":"2015","journal-title":"Oncotarget"},{"issue":"34","key":"ref57","doi-asserted-by":"crossref","first-page":"36675","DOI":"10.18632\/oncotarget.5383","article-title":"MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma","volume":"6","author":"AR Glover","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/bcr432","article-title":"Liposome-based drug delivery in breast cancer treatment","volume":"4","author":"JW Park","year":"2002","journal-title":"Breast cancer research: BCR"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2014a key regulatory factor in tumour growth","volume":"2","author":"AL Harris","year":"2002","journal-title":"Nature reviews Cancer"},{"issue":"6955","key":"ref60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/425247a","article-title":"Cancer: cues for migration","volume":"425","author":"R Bernards","year":"2003","journal-title":"Nature"},{"issue":"7","key":"ref61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2012.05.006","article-title":"Bioengineered microbes in disease therapy","volume":"18","author":"AW Paton","year":"2012","journal-title":"Trends in molecular medicine"},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"AN Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"ref63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"A Klabatsa","year":"2006","journal-title":"Lung Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T08:42:03Z","timestamp":1603183323000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186137"}},"subtitle":[],"editor":[{"given":"Arun","family":"Rishi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186137","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]}}}